Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.

NCT Number	NCT07468071
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Enrollment	40 participants
Start Date	2026-06-08
Primary Completion	2029-06-15 (estimated)
Study Completion	2029-09-17 (estimated)
Updated on ClinicalTrials.gov	2026-07-14